ESR1 and breast cancer: Hormone receptor positive (ER and/or PR positive) and HER2− negative (HR+/HER2−) breast cancer is both the most frequently diagnosed subtype (73%) in the US and is associated with the best prognosis, with a 5-year relative survival rate of 92% [3].